-
Letter: Association of myokines with disease progression and outcomes in patients with alcohol-associated liver disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-19 Jianyu Lv, Yize Ying, Chenfei Du
This article is linked to Kaur et al papers. To view these articles, visit https://doi.org/10.1111/apt.18202 and https://doi.org/10.1111/apt.18279
-
Letter: Association of myokines with disease progression and outcomes in patients with alcohol-associated liver disease—Authors' reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-19 Parminder Kaur, Nipun Verma
This article is linked to Kaur et al papers. To view these articles, visit https://doi.org/10.1111/apt.18202 and https://doi.org/10.1111/apt.18238
-
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-19 Anna Fettiplace, John Marcinak, Michael Merz, Hui-Talia Zhang, Luciana Kikuchi, Arie Regev, Melissa Palmer, Don Rockey, Robert Fontana, Paul H. Hayashi, Hans L. Tillmann, Adrian M. Di Bisceglie, James H. Lewis
-
Editorial: Advancing care in Crohn's disease—Time to standardise bowel preparation scales Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-19 Mohammad Shehab, Talat Bessissow
This article is linked to Solitano et al papers. To view these articles, visit https://doi.org/10.1111/apt.18210 and https://doi.org/10.1111/apt.18288
-
Editorial: Advancing care in Crohn's disease—Time to standardise bowel preparation scales. Authors' reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-19 Virginia Solitano, Christopher Ma, Vipul Jairath
This article is linked to Solitano et al papers. To view these articles, visit https://doi.org/10.1111/apt.18210 and https://doi.org/10.1111/apt.18269
-
Letter: Ulcerative proctitis, a step towards addressing the knowledge gap, and a call for greater detail, in trial data—Authors' reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-18 Rocío Ferreiro-Iglesias, Manuel Barreiro-de Acosta
This article is linked to Ferreiro-Iglesias et al papers. To view these articles, visit https://doi.org/10.1111/apt.18133 and https://doi.org/10.1111/apt.18248
-
Letter: Ulcerative proctitis—A step towards addressing the knowledge gap, and a call for greater detail, in trial data Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-18 John David Chetwood, Nik Sheng Ding
This article is linked to Ferreiro-Iglesias et al papers. To view these articles, visit https://doi.org/10.1111/apt.18133 and https://doi.org/10.1111/apt.18281
-
Letter: Enhancing gastric cancer prevention—The need for a comprehensive three-tier emergency management strategy. Authors' reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-18 Irene Ligato, Bruno Annibale, Gianluca Esposito
This article is linked to Ligato et al papers. To view these articles, visit https://doi.org/10.1111/apt.17872 and https://doi.org/10.1111/apt.18260
-
Letter: Enhancing gastric cancer prevention—The need for a comprehensive three-tier emergency management strategy Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-18 Zhangbin Zhou, Liu Wang, Yunfeng Chen
This article is linked to Ligato et al papers. To view these articles, visit https://doi.org/10.1111/apt.17872 and https://doi.org/10.1111/apt.18283
-
Strengthening the foundation of African microbiome research: strategies for standardized data collection Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-09-19 Soumaya Kouidhi, Ovokeraye H. Oduaran
The current state of microbiome research in Africa can be leveraged to encourage the development and implementation of standardized processes for data collection and management. In this Comment, we provide some recommendations to enable the research community to fully harness the richness of the microbiome of African populations and potential opportunities therein.
-
High-risk varices in patients with Child-Pugh-Turcotte B and C: consider band ligation with carvedilol for preventing first variceal bleeding, especially in patients with MASLD-associated cirrhosis Gut (IF 23.0) Pub Date : 2024-09-18 Alexander Zipprich, Ruben Hernaez
International guidelines recommend that primary prophylaxis of varices in patients with cirrhosis be either non-selective beta-blockers (NSBBs) or variceal band ligation (VBL). These recommendations are based on studies that include both compensated and decompensated patients. Notably, the European Association for the Study of the Liver 2018 guidelines recognise a gap in the efficacy of NSBB therapy
-
Statins for MAFLD/MASH: another brick in the wall while waiting for final answers Gut (IF 23.0) Pub Date : 2024-09-18 Jaime Bosch
I read with pleasure the paper by Zhou et al 1 analysing the long-term clinical outcomes and changes in liver elastography associated with statin usage in patients with metabolic-associated steatotic liver disease (MASLD). This is a population-based study of 7988 patients selected from a total of 17 849 MASLD patients seen in 16 centres in Europe, America and Asia and who had also transient elastography
-
Commentary on: the management of patients with gastric intestinal metaplasia Gut (IF 23.0) Pub Date : 2024-09-18 David Y Graham, Yi-Chia Lee
Recently, Gut published a review of guidelines for the management of gastric intestinal metaplasia (GIM) with the goal of promoting harmonisation of the guidelines regarding indications for endoscopic screening for gastric cancer and GIM detection/staging, metrics for high-quality endoscopy and non-endoscopic interventions for gastric cancer prevention in patients with GIM.1 GIM is not a disease per
-
Cold EMR, hot EMR or ESD for large benign adenoma: not one size fits all Gut (IF 23.0) Pub Date : 2024-09-17 Veronique Van der Voort, Cesare Hassan, Alessandro Repici, Romain Legros, Mathieu Pioche, Jérémie Jacques
We read with great interest the study by O’Sullivan et al ,1 examining the technical and procedural outcomes of Cold Endoscopic Mucosal Resection (C-EMR) versus Hot EMR (H-EMR). We congratulate the authors for conducting this important research, which adds valuable information to the body of knowledge guiding our choice of the optimal treatment modality for large, benign colorectal polyps. However
-
End-to-end donor screening and manufacturing controls: complementary quality-based strategies to minimize patient risk for donor-derived microbiome therapeutics. Gut Microbes (IF 12.2) Pub Date : 2024-09-18 Jason Goldsmith,Sarah Tomkovich,John G Auniņš,Barbara H McGovern,Jennifer C Mahoney,Brooke R Hasson,Christopher W J McChalicher,David S Ege
Advances in microbiome therapeutics have been motivated by a deeper understanding of the role that the gastrointestinal microbiome plays in human health and disease. The FDA approval of two stool-derived live biotherapeutic products (LBPs), REBYOTA® 150 mL enema (fecal microbiota, live-jslm; formerly RBX2660) and VOWST® oral capsules (fecal microbiota spores, live-brpk; formerly SER-109), for the prevention
-
Molecular serotyping of diarrheagenic Escherichia coli with a MeltArray assay reveals distinct correlation between serotype and pathotype. Gut Microbes (IF 12.2) Pub Date : 2024-09-18 Chen Du,Yiqun Liao,Congcong Ding,Jiayu Huang,Shujuan Zhou,Yiyan Xu,Zhaohui Yang,Xiaolu Shi,Yinghui Li,Min Jiang,Le Zuo,Minxu Li,Shengzhe Bian,Na Xiao,Liqiang Li,Ye Xu,Qinghua Hu,Qingge Li
Diarrheagenic Escherichia coli serotypes are associated with various clinical syndromes, yet the precise correlation between serotype and pathotype remains unclear. A major barrier to such studies is the reliance on antisera-based serotyping, which is culture-dependent, low-throughput, and cost-ineffective. We have established a highly multiplex PCR-based serotyping assay, termed the MeltArray E. coli
-
Gut microbiota-derived butyrate selectively interferes with growth of carbapenem-resistant Escherichia coli based on their resistance mechanism. Gut Microbes (IF 12.2) Pub Date : 2024-09-18 Eva Happ,Kora Schulze,Zinia Afrin,Sabrina Woltemate,Pia Görner,Stefan Ziesing,Dirk Schlüter,Robert Geffers,Volker Winstel,Marius Vital
We investigated consequences of resistance acquisition in Escherichia coli clinical isolates during anaerobic (continuous culture) growth and examined their sensitivity to butyrate, a hallmark metabolite of healthy gut microbiota. Strains were stratified based on carrying either a carbapenemase (CARB) or displaying porin malfunctioning (POR). POR displayed markedly altered growth efficiencies, lower
-
Letter: Assessing the prognostic value of agile 3+ and agile 4 scores in predicting chronic kidney disease development in patients with metabolic dysfunction‐associated steatotic liver disease Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-18 Zhenzhi Qin, Yan Xu
LINKED CONTENTThis article is linked to Jung et al paper. To view this article, visit https://doi.org/10.1111/apt.18213
-
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-17 María Chaparro, Sandra Hermida, Diana Acosta, Agnès Fernández-Clotet, Manuel Barreiro-de Acosta, Álvaro Hernández Martínez, Maite Arroyo, Marta Maia Bosca-Watts, M. Teresa Diz-Lois Palomares, Luis Menchén, Jesús Martínez Cadilla, Eduardo Leo-Carnerero, Carmen Muñoz Villafranca, Mónica Sierra-Ausín, Yago González-Lama, Sabino Riestra, Pau Sendra Rumbeu, M. José Cabello Tapia, Irene García de la Filia
-
ADP-heptose attenuates Helicobacter pylori-induced dendritic cell activation. Gut Microbes (IF 12.2) Pub Date : 2024-09-17 Theresa Neuper,Tobias Frauenlob,Hieu-Hoa Dang,Peter W Krenn,Gernot Posselt,Christof Regl,Nikolaus Fortelny,Veronika Schäpertöns,Michael S Unger,Gunda Üblagger,Daniel Neureiter,Iris Mühlbacher,Michael Weitzendorfer,Franz Singhartinger,Klaus Emmanuel,Christian G Huber,Silja Wessler,Fritz Aberger,Jutta Horejs-Hoeck
Sophisticated immune evasion strategies enable Helicobacter pylori (H. pylori) to colonize the gastric mucosa of approximately half of the world's population. Persistent infection and the resulting chronic inflammation are a major cause of gastric cancer. To understand the intricate interplay between H. pylori and host immunity, spatial profiling was used to monitor immune cells in H. pylori infected
-
Empowering probiotics with high xanthine transport for effective hyperuricemia management. Gut Microbes (IF 12.2) Pub Date : 2024-09-17 Zhen-Ping Zou,Ju-Ling Li,Yi-Fan Zhang,Ying Zhou,Bang-Ce Ye
Hyperuricemia, a prevalent metabolic disorder, poses a susceptibility to various complications. The conventional pharmacotherapeutic approaches for hyperuricemia often entail notable adverse effects, posing substantial clinical challenges. Hence, the imperative lies in the development of novel, safe and effective strategies for preventing and treating hyperuricemia. Here, we developed a probiotic Escherichia
-
Prebiotic inulin controls Th17 cells mediated central nervous system autoimmunity through modulating the gut microbiota and short chain fatty acids. Gut Microbes (IF 12.2) Pub Date : 2024-09-17 Ning Li,Xinyan Han,Ming Ruan,Fei Huang,Liu Yang,Tianhao Xu,Huijun Wang,Hui Wu,Songshan Shi,Yongjun Wang,Xiaojun Wu,Shunchun Wang
Multiple sclerosis (MS) is an autoimmune disease characterized by inflammatory demyelination occurring in the central nervous system (CNS). Inulin is a common prebiotic that can improve metabolic disorders by modulating the gut microbiota. However, its capacity to affect CNS autoimmunity is poorly recognized. Experimental autoimmune encephalomyelitis (EAE) is a classical mouse model of MS. Herein,
-
Gut microbe-host interactions in post-COVID syndrome: a debilitating or restorative partnership? Gut Microbes (IF 12.2) Pub Date : 2024-09-17 Torsten P M Scheithauer,Roy C Montijn,Arnout Mieremet
Post-COVID syndrome (PCS) patients have reported a wide range of symptoms, including fatigue, shortness of breath, and diarrhea. Particularly, the presence of gastrointestinal symptoms has led to the hypothesis that the gut microbiome is involved in the development and severity of PCS. The objective of this review is to provide an overview of the role of the gut microbiome in PCS by describing the
-
Effect of diet on the gut mycobiome and potential implications in inflammatory bowel disease. Gut Microbes (IF 12.2) Pub Date : 2024-09-17 J Buttar,E Kon,A Lee,G Kaur,G Lunken
The gut microbiome is a complex, unique entity implicated in the prevention, pathogenesis, and progression of common gastrointestinal diseases. While largely dominated by bacterial populations, advanced sequencing techniques have identified co-inhabiting fungal communities, collectively referred to as the mycobiome. Early studies identified that gut inflammation is associated with altered microbial
-
Editorial: Does ESWL‐ERCP for pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis? Authors' reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-17 Yu Liu, Liang‐Hao Hu
LINKED CONTENTThis article is linked to Yiu et al papers. To view these articles, visit https://doi.org/10.1111/apt.18224 and https://doi.org/10.1111/apt.18253
-
Editorial: Does ESWL‐ERCP for pancreatic duct stone removal change the natural course of symptomatic chronic calcific pancreatitis? Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-17 Richard Kozarek
LINKED CONTENTThis article is linked to Yiu et al papers. To view these articles, visit https://doi.org/10.1111/apt.18224 and https://doi.org/10.1111/apt.18284
-
Enterotoxigenic Escherichia coli heat labile enterotoxin affects neutrophil effector functions via cAMP/PKA/ERK signaling. Gut Microbes (IF 12.2) Pub Date : 2024-09-16 Jinglin Ma,Leen Hermans,Matthias Dierick,Hans Van der Weken,Eric Cox,Bert Devriendt
Enterotoxigenic Escherichia coli (ETEC) are a major cause of diarrheal illness in humans and animals, induced by enterotoxins produced by these pathogens. Despite the crucial role of neutrophils in combatting bacterial infections, our understanding of how enterotoxins impact neutrophil function is limited. To address this knowledge gap, we used heat-labile enterotoxin (LT) and heat-stable enterotoxin
-
The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease. Gut Microbes (IF 12.2) Pub Date : 2024-09-16 Kallie E Hays,Jacob M Pfaffinger,Rebecca Ryznar
Short-chain fatty acids (SCFAs) - acetate, propionate, and butyrate - are important bacterial fermentation metabolites regulating many important aspects of human physiology. Decreases in the concentrations of any or multiple SCFAs are associated with various detrimental effects to the host. Previous research has broadly focused on gut microbiome produced SCFAs as a group, with minimal distinction between
-
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD Gut (IF 23.0) Pub Date : 2024-09-13 Giorgos Bamias, Paola Menghini, Theresa T Pizarro, Fabio Cominelli
TNF-like cytokine 1A (TL1A) and its functional receptor, death-domain receptor 3 (DR3), are members of the TNF and TNFR superfamilies, respectively, with recognised roles in regulating innate and adaptive immune responses; additional existence of a decoy receptor, DcR3, indicates a tightly regulated cytokine system. The significance of TL1A:DR3 signalling in the pathogenesis of inflammatory bowel disease
-
Metabolic reprogramming by mutant GNAS creates an actionable dependency in intraductal papillary mucinous neoplasms of the pancreas Gut (IF 23.0) Pub Date : 2024-09-13 Yuki Makino, Kimal I Rajapakshe, Benson Chellakkan Selvanesan, Takashi Okumura, Kenjiro Date, Prasanta Dutta, Lotfi Abou-Elkacem, Akiko Sagara, Jimin Min, Marta Sans, Nathaniel Yee, Megan J Siemann, Jose Enriquez, Paytience Smith, Pratip Bhattacharya, Michael Kim, Merve Dede, Traver Hart, Anirban Maitra, Fredrik Ivar Thege
Background Oncogenic ‘hotspot’ mutations of KRAS and GNAS are two major driver alterations in intraductal papillary mucinous neoplasms (IPMNs), which are bona fide precursors to pancreatic ductal adenocarcinoma. We previously reported that pancreas-specific Kras G12D and Gnas R201C co-expression in p48Cre; KrasLSL-G12D; Rosa26LSL-rtTA; Tg (TetO-GnasR201C) mice ( ‘Kras;Gnas ’ mice) caused development
-
Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989 Gut (IF 23.0) Pub Date : 2024-09-12 Lung Yi Mak, Christine I Wooddell, Oliver Lenz, Thomas Schluep, James Hamilton, Heather L Davis, Xianhua Mao, Wai-Kay Seto, Michael Biermer, Man-Fung Yuen
Background and aims RNA interference has been extensively explored in patients with chronic hepatitis B (CHB) infection. We aimed to characterise the long-term efficacy of small interfering RNA (siRNA) on hepatitis B surface antigen (HBsAg) suppression. Methods We prospectively followed up participants with CHB who received siRNA, either ARC-520 or JNJ-73763989 (JNJ-3989), in combination with nucleoside
-
-
Editorial: Plants against animals Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-13 Einar S. Björnsson
LINKED CONTENTThis article is linked to Choi et al paper. To view this article, visit https://doi.org/10.1111/apt.18116
-
Gut microbiota mediate early life stress-induced social dysfunction and anxiety-like behaviors by impairing amino acid transport at the gut Gut Microbes (IF 12.2) Pub Date : 2024-09-11 Jiushuang Zhu, Zhuoting Zhong, Lijie Shi, Ling Huang, Chunqiao Lin, Yan He, Xiuwen Xia, Tiane Zhang, Weijun Ding, Youjun Yang
Early life stress alters gut microbiota and increases the risk of neuropsychiatric disorders, including social deficits and anxiety, in the host. However, the role of gut commensal bacteria in earl...
-
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases Nat. Rev. Gastroenterol. Hepatol. (IF 45.9) Pub Date : 2024-09-12 Giovanni Cammarota, Gianluca Ianiro
Gastroenterology as a specialty can make a substantial contribution to reducing the carbon footprint of the health-care system. Concrete actions are needed to increase awareness, education and evidence-based knowledge on eco-sustainable diagnostic and therapeutic approaches to digestive diseases.
-
Extending inflamed-class signature to predict immune checkpoint inhibitor-based combination therapy in hepatocellular carcinoma Gut (IF 23.0) Pub Date : 2024-09-11 Wenhua You, Chupeng Hu, Mengya Zhao, Yuhan Zhang, Jinying Lu, Yedi Huang, Ling Li, Yun Chen
Recently, we were intrigued by a recent study by Montironi et al ,1 in which they discovered that an inflamed subclass in hepatocellular carcinoma (HCC) patients is associated with a response to immunotherapy. The authors used a 20-gene signature to distinguish these patients and further found different immune infiltration between inflamed and non-inflamed class at the bulk level. We commend the authors
-
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma Gut (IF 23.0) Pub Date : 2024-09-11 Jasmin Elurbide, Leticia Colyn, Maria U Latasa, Iker Uriarte, Stefano Mariani, Amaya Lopez-Pascual, Emiliana Valbuena, Borja Castello-Uribe, Robert Arnes-Benito, Elena Adan-Villaescusa, Luz A Martinez-Perez, Mikel Azkargorta, Felix Elortza, Hanghang Wu, Marcin Krawczyk, Kai Markus Schneider, Bruno Sangro, Luca Aldrighetti, Francesca Ratti, Andrea Casadei Gardini, Jose J G Marin, Irene Amat, Jesus M
Background Cholangiocarcinoma (CCA) is a very difficult-to-treat cancer. Chemotherapies are little effective and response to immune checkpoint inhibitors is limited. Therefore, new therapeutic strategies need to be identified. Objective We characterised the enzyme protein arginine-methyltransferase 5 (PRMT5) as a novel therapeutic target in CCA. Design We evaluated the expression of PRMT5, its functional
-
Gut microbiota-mediated C-sulfonate metabolism impairs the bioavailability and anti-cholestatic efficacy of andrographolide. Gut Microbes (IF 12.2) Pub Date : 2024-09-12 Dafu Tang,Wanyu Hu,Bingxuan Fu,Xiaojie Zhao,Guoquan You,Cong Xie,Hong Yu Wang,Xueni Guo,Qianbing Zhang,Zhongqiu Liu,Ling Ye
Cholestatic liver injury results from the accumulation of toxic bile acids in the liver, presenting a therapeutic challenge with no effective treatment available to date. Andrographolide (AP) has exhibited potential as a treatment for cholestatic liver disease. However, its limited oral bioavailability poses a significant obstacle to harnessing its potent therapeutic properties and restricts its clinical
-
Fecal microbiota transplantation derived from mild cognitive impairment individuals impairs cerebral glucose uptake and cognitive function in wild-type mice: Bacteroidetes and TXNIP-GLUT signaling pathway. Gut Microbes (IF 12.2) Pub Date : 2024-09-12 Tao Wang,Ling Hao,Kexin Yang,Wenjing Feng,Zhiting Guo,Miao Liu,Rong Xiao
Gut microbiome dysbiosis has been widely implicated in cognitive impairment, but the identity of the specific bacterial taxa and mechanisms are not fully elucidated. Brain glucose hypometabolism coincides with the cognitive decline. This study explored the link among cognition, gut microbiota and glucose uptake based on the fecal microbiota transplantation from mild cognitive impairment individuals
-
Guidelines in Practice: Alcohol-Associated Liver Disease. Am. J. Gastroenterol. (IF 8.0) Pub Date : 2024-09-12 Ashwani K Singal,Loretta Jophlin,Vijay H Shah
-
Predicting complications in paediatric ulcerative colitis: A longitudinal multicentre cohort study Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-10 Merle Claßen, Benjamin Schiller, Jan Däbritz
-
The hidden base of the iceberg: gut peptidoglycome dynamics is foundational to its influence on the host Gut Microbes (IF 12.2) Pub Date : 2024-09-06 Richard Wheeler, Ivo Gomperts Boneca
The intestinal microbiota of humans includes a highly diverse range of bacterial species. All these bacteria possess a cell wall, composed primarily of the macromolecule peptidoglycan. As such, the...
-
Microbiome 2.0: lessons from the 2024 Gut Microbiota for Health World Summit Gut Microbes (IF 12.2) Pub Date : 2024-09-10 Sushrut Jangi, Gail Hecht
This Meeting Summary highlights the key insights from the 12th meeting of the Gut Microbiota for Health World Summit, held in Washington, DC, organized by the American Gastroenterological Associati...
-
AlphaMissense versus laboratory-based pathogenicity prediction of 13 novel missense CPA1 variants from pancreatitis cases Gut (IF 23.0) Pub Date : 2024-09-10 Máté Sándor, Isabelle Scheers, Atsushi Masamune, Heiko Witt, Jessica LaRusch, Jian-Min Chen, Balázs Csaba Németh, Andrea Geisz, Aliye Uc, Miklós Sahin-Tóth
We have read with great interest the study by Wang et al 1 in which the authors evaluated the utility of the AlphaMissense prediction programme2 (https://alphamissense.hegelab.org) in the classification of missense CPA1 variants with respect to pathogenicity in chronic pancreatitis. While the AI-driven prediction performed relatively well, the authors highlighted potential shortcomings that can limit
-
Differences in disease characteristics and treatment exposures between paediatric and adult‐onset inflammatory bowel disease using a registry‐based cohort Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-11 Maya Granot, Uri Kopylov, Nurit Loberman‐Nachum, Alexander Krauthammer, Chaya Mushka Abitbol, Shomron Ben‐Horin, Batia Weiss, Yael Haberman
-
Microbiota-induced S100A11-RAGE axis underlies immune evasion in right-sided colon adenomas and is a therapeutic target to boost anti-PD1 efficacy Gut (IF 23.0) Pub Date : 2024-09-09 Qiming Zhou, Linhan Lei, Junhong Cheng, Junyou Chen, Yuyang Du, Xuehua Zhang, Qing Li, Chuangen Li, Haijun Deng, Chi Chun Wong, Baoxiong Zhuang, Guoxin Li, Xiaowu Bai
Background Tumourigenesis in right-sided and left-sided colons demonstrated distinct features. Objective We aimed to characterise the differences between the left-sided and right-sided adenomas (ADs) representing the early stage of colonic tumourigenesis. Design Single-cell and spatial transcriptomic datasets were analysed to reveal alterations between right-sided and left-sided colon ADs. Cells, animal
-
Global differences in the management of alcohol-associated hepatitis. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-09-10 Hanna Blaney,Luis Antonio Díaz,Nhi Li,Gurpreet Malhi,Rokhsana Mortuza,Xiaolong Qi,Anand V Kulkarni,Ramon Bataller,Joaquin Cabezas,Alexandre Louvet,Elliot B Tapper,Juan Pablo Arab
-
Segmental patterning of microbiota and immune cells in the murine intestinal tract. Gut Microbes (IF 12.2) Pub Date : 2024-09-10 Harithaa Anandakumar,Ariana Rauch,Moritz I Wimmer,Alex Yarritu,Gudrun Koch,Victoria McParland,Hendrik Bartolomaeus,Nicola Wilck
The intestine exhibits distinct characteristics along its length, with a substantial immune cell reservoir and diverse microbiota crucial for maintaining health. This study investigates how anatomical location and regional microbiota influence intestinal immune cell abundance. Using conventionally colonized and germ-free mice, segment-specific immune cell composition and microbial communities were
-
Low socioeconomic status exacerbates unmet health‐related needs in patients with autoimmune hepatitis Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-10 Carolyn Singleton, Allie Carter, Brittany Baker, Emma Jones, Kelsey Green, Craig Lammert, Lauren D. Nephew
-
Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2–F3 fibrosis Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-10 Yusuf Yilmaz
LINKED CONTENTThis article is linked to McPherson et al papers. To view these articles, visit https://doi.org/10.1111/apt.18061 and https://doi.org/10.1111/apt.18209.
-
Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-10 Stuart McPherson, Jessica K. Dyson, Laura Jopson, Steven Masson, Preya Patel, Quentin M. Anstee
LINKED CONTENTThis article is linked to McPherson et al papers. To view these articles, visit https://doi.org/10.1111/apt.18061 and https://doi.org/10.1111/apt.18171.
-
Glycaemic control is a modifiable risk factor for hepatocellular carcinoma and liver‐related mortality in patients with diabetes Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-10 Xianhua Mao, Ka‐Shing Cheung, Jing‐Tong Tan, Lung‐Yi Mak, Chi‐Ho Lee, Chi‐Leung Chiang, Ho‐Ming Cheng, Rex Wan‐Hin Hui, Wai K. Leung, Man‐Fung Yuen, Wai‐Kay Seto
-
Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-10 Elliot B. Tapper, Neehar D. Parikh
LINKED CONTENTThis article is linked to Tapper et al papers. To view these articles, visit https://doi.org/10.1111/apt.18127 and https://doi.org/10.1111/apt.18257
-
Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-10 Mingsi Zhang, Yunmeng Nie
LINKED CONTENTThis article is linked to Tapper et al papers. To view these articles, visit https://doi.org/10.1111/apt.18127 and https://doi.org/10.1111/apt.18259
-
Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-10 Senlin Ye, Jinli Liu, Ruyi Zhou
LINKED CONTENTThis article is linked to Tran et al papers. To view these articles, visit https://doi.org/10.1111/apt.18024 and https://doi.org/10.1111/apt.18265
-
Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance: Authors' reply Aliment. Pharm. Ther. (IF 6.6) Pub Date : 2024-09-10 Sally Tran, Linda Henry, Mindie H. Nguyen
LINKED CONTENTThis article is linked to Tran et al papers. To view these articles, visit https://doi.org/10.1111/apt.18024 and https://doi.org/10.1111/apt.18245.
-
Prophylactic abdominal drainage after distal pancreatectomy: really unnecessary? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Yuan Sun,Yan Li,Kezhen Zong,Ning Jiang,Baoyong Zhou
-
Natural history and progression of metabolic dysfunction-associated steatotic liver disease. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Hannes Hagström,Ying Shang,Hannes Hegmar,Patrik Nasr
The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long. A minority of patients develop inflammation and risk progressive fibrosis that can result in cirrhosis. Progression to cirrhosis occurs in 3-5% of patients and often takes more than 20 years. This narrative review presents
-
Irritable bowel syndrome: an urgent issue. Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 Chrissie Pearson
-
Blood tests for colorectal cancer: practical or premature? Gastroenterol. Hepatol. (IF 30.9) Pub Date : 2024-10-01 The Lancet Gastroenterology Hepatology